Young Innovators of Medicines

younginnovatorsofmedicines.nl

The Young Innovators of Medicines form the youth branch of the Innovative Medicines Association. This is a trade association for 44 drug companies with a Dutch branch. The youth branch was founded in 2013, under the then name Jong Nefarma. The members of the Association have put forward 22 high potentials to participate in the youth department. In recent years, young people themselves have defined themes such as talent and development, partnership with other young (care) associations, connecting young people within the Association, and debate and advice on important topics in the pharmaceutical industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

SILVERBACK THERAPEUTICS AND ARS PHARMACEUTICALS ANNOUNCE MERGER

Silverback Therapeutics and ARS Pharmaceuticals | July 22, 2022

news image

Silverback Therapeutics, Inc. and ARS Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. The combined company is expected to have approximately $265M in cash, cash ...

Read More

PHARMA TECH

CORNING ACCELERATES DELIVERY OF LIFE-SAVING TREATMENTS AND CRITICAL DRUGS WITH EXPANDED PHARMACEUTICAL GLASS PACKAGING PORTFOLIO

Corning Incorporated | November 19, 2021

news image

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Velocity Vials can deliver better econ...

Read More

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

news image

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More

BUSINESS INSIGHTS

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

news image

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More
news image

PHARMA TECH

SILVERBACK THERAPEUTICS AND ARS PHARMACEUTICALS ANNOUNCE MERGER

Silverback Therapeutics and ARS Pharmaceuticals | July 22, 2022

Silverback Therapeutics, Inc. and ARS Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. The combined company is expected to have approximately $265M in cash, cash ...

Read More
news image

PHARMA TECH

CORNING ACCELERATES DELIVERY OF LIFE-SAVING TREATMENTS AND CRITICAL DRUGS WITH EXPANDED PHARMACEUTICAL GLASS PACKAGING PORTFOLIO

Corning Incorporated | November 19, 2021

Corning Incorporated introduced Corning Velocity® Vials, specially engineered Type I borosilicate vials externally coated with the company’s proprietary technology, which are helping industry-leading drugmakers respond to the pandemic at speed. The increased efficiency and throughput enabled by Velocity Vials can drive faster manufacturing of COVID-19 vaccines, helping address industry supply chain challenges and meet global demand. Velocity Vials can deliver better econ...

Read More
news image

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More
news image

BUSINESS INSIGHTS

CELLUSION AND CELREGEN A MEMBER OF FOSUN PHARMA, ENTER INTO EXCLUSIVE LICENSE AGREEMENT OF CLS001 FOR A CORNEAL ENDOTHELIAL CELL REGENERATIVE

Cellusion and Celregen | September 12, 2022

Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...

Read More